Market Access

Study examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.

Payers and pharma companies seek outcomes data for evidence-based reimbursement deals.

February 28, 2017

Congress is poised to tackle exorbitant drug prices through health reform and FDA legislation.

Pharm Exec talks to Mel Formica, Takeda’s Vice President of Global Market Access, about what he sees as the challenges and opportunities in 2017, and how he envisions the industries market access capabilities evolving.

Pharm Exec speaks to ICON's Ramita Tandon about how the UK and European regulators' market access plans for 2017 will affect the industry.

With the push toward value-based heathcare set to accelerate even more in 2017, Takeda’s VP of global market access discusses the evolution of this all-important engine for medical innovation and bottom-line returns.

An industry-based working group presents a common standards and definition framework for “Access” competencies in pharma-as a starting point in solving the current shortage of talent and leaders for this widening set of activities.

The surprise victory of Donald Trump opens the door to new strategies for providing healthcare to Americans, including coverage and oversight of prescription drugs.

Pharm Exec sits down with Anthony Marucci, co-founder and CEO of Celldex, a stealth player in the immunotherapy field.

A new industry working group explores alternative drug funding options in Europe-and asks key stakeholders in the region to join the discussion.

William Looney speaks with DIA's Global Chief Executive to see how the organization is repositioning itself as the go-to place for the independent insights in a business with no boundaries.

Whatever used to be wrong with the world of big Pharma could be fixed with a single tag phrase: emerging country markets. Most of the majors have invested heavily in this geographic segment, and the biggest of the big-companies like Novartis-now rely on it for more than a quarter of their global sales. Like all good things, however, there are shadows amidst the sunlight, and the task of turning volume sales into sustainable profits is getting harder.

Pharm Exec talks with David Dosa, a leading physician in geriatric medicine, whose famous work with a cat named oscar in end-of-life diagnostics became the stuff of therapeutic legend.

As vital contributors to hospital disaster preparedness, the pharma industry has a role to play in making sure medical networks have what they need to meet the unforeseen, including future disasters.

In the past few years, we’ve seen the biopharmaceutical industry begin to shift from a one-size-fits-all blockbuster approach toward an individualized, precision science model. This transformation has propelled companion diagnostics (CDx) into playing a more critical role than ever in the commercialization of biopharmaceutical therapeutics.

A new and more compelling strategy must be crafted to engage critics on drug pricing and bolster biopharmaceuticals as a leader in technological innovations that lower health costs overall.

A response to the therapeutic potential of using bacteriophages as antibiotics - though doubtful phages can be applied as antibiotics have, they do offer mighty weapons against threats of antibiotic resistance.

Ed Schoonveld highlights the wait confronting lung cancer patients seeking Opdivo in the UK. Can we find room for compromise?

A non-antibiotic bactericidal treatment for humans was first proven effective in 1919. Ansis Helmanis asks why they are not commercially available in the United States.

Commercial success for pharma brands now demands proactive strategies and interventions

Susan Crowley reviews the hotly debated agenda items from last month's World Health Assembly (WHA) in Geneva, Switzerland.

NICE's proposed Innovation Office emerges with a new name. Leela Barham reports.

What’s new in the growing field of global market access?

Positive early stage trial results for Biogen’s aducanumab has renewed hope for effective solutions for Alzheimer's Disease, but many challenges remain in finding and funding new treatment, writes Ed Schoonveld.